Here’s a bold statement: The future of cancer care is being reshaped by technology, sustainability, and personalized medicine, but not everyone agrees on how to get there. Martin Zapata Laguado, a Medical Oncologist and Internal Medicine Physician at the National Cancer Institute of Colombia, recently shared eye-opening insights from EMUC 2025 that challenge conventional practices and spark debate. Let’s dive into his key takeaways—and trust me, this is the part most people miss.
AI in Clinical Practice: The Double-Edged Sword
Zapata Laguado highlights the growing role of Artificial Intelligence (AI) in daily clinical practice, but here’s where it gets controversial: while AI promises efficiency, its integration requires patients to understand and trust this technology. He emphasizes the need for better patient education—a point that’s often overlooked. But is the healthcare system ready to bridge this knowledge gap?
Screening Debates: Kidney and Bladder Cancer
Current evidence, as Zapata Laguado notes, does not support widespread screening for kidney cancer—except in high-risk hereditary cases. Similarly, bladder cancer screening remains inconclusive, with dipstick testing still under evaluation. But here’s the kicker: Should we wait for stronger evidence, or act now for high-risk groups?
Imaging vs. Biopsy: A Replacement in Sight?
One of the most thought-provoking points: Can imaging replace biopsy? Zapata Laguado argues that, for now, the answer is no. Stronger evidence and nuclear imaging correlations are still needed. But what if future advancements prove otherwise? Could this shift the entire diagnostic landscape?
Prostate Cancer Screening: Essential but Evolving
While prostate cancer screening remains crucial, the focus is shifting toward risk-based, randomized trials to optimize resources. But is this approach equitable? Could it leave some populations underserved?
Sustainability in Cancer Care: Small Changes, Big Impact
Zapata Laguado sheds light on sustainability, advocating for hypofractionation in radiation therapy and smarter resource use to reduce the carbon footprint in bladder and prostate cancer care. Even small practice changes in surgery, he notes, can significantly cut resource consumption. But are healthcare providers willing to adopt these changes, or is the status quo too entrenched?
Biomarkers and Personalization: The Future of Oncology
Biomarkers, as discussed by Yuksel Urun, can personalize treatment and reduce therapy intensity, cutting down on mobility and resource use. But is personalized medicine accessible to all, or will it widen healthcare disparities?
Final Thoughts and a Call to Action
Zapata Laguado’s insights from EMUC 2025 paint a picture of a rapidly evolving oncology landscape. From AI integration to sustainability, the challenges are clear—but so are the opportunities. What’s your take? Do you agree with these approaches, or do you see potential pitfalls? Let’s spark a conversation in the comments!
